MedTrace Logo

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

NCT06309147 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-03-18

No results posted yet for this study

Summary

A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

BMS-9894923

50 mg capsules, oral administration

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Allyx Therapeutics

    lead INDUSTRY

Principal Investigators

  • Laurie Sanders, Ph.D · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2025-02-15
Completion
2025-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06309147 on ClinicalTrials.gov